BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Egrifta WR (Tesamorelin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Egrifta WR (Tesamorelin)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03150511-1018@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Egrifta WR (Tesamorelin): Phase 2 readout est. (NCT03150511)
DESCRIPTION:Egrifta WR (Tesamorelin)\, phase 2.\nStudy: Tesamorelin to Impr
 ove Functional Outcomes After Peripheral Nerve Injury\nEstimated primary c
 ompletion: December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tesamorelin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03150511
URL:https://assetmemo.bio/drug/tesamorelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06554717-1018@assetmemo.bio
DTSTAMP:20261121T005615Z
DTSTART;VALUE=DATE:20280616
DTEND;VALUE=DATE:20280617
SUMMARY:Egrifta WR (Tesamorelin): Phase 2 readout est. (NCT06554717)
DESCRIPTION:Egrifta WR (Tesamorelin)\, phase 2\, HIV.\nStudy: Tesamorelin a
 s an Adjunct to Exercise for Improving Physical Function in HIV\nEstimated
  primary completion: 16 June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tesamorelin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06554717
URL:https://assetmemo.bio/drug/tesamorelin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
